Current Clinical Trials

Clinical Trials/ResearchCurrent Clinical Trials

We can help you determine the optimal approach. Our clinical trials & other research efforts are summarized below.

Current Clinical Trials for the Brain Tumor Center

NEWLY OPENED CLINICAL TRIAL

  • Boston Biomedical: A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma (GBM) Following Initial Therapy (NCT03149003)

 

ACTIVELY RECRUITING STUDIES

Primary Brain Cancer

  • AbbVie / RTOG: A Study of ABT-414 in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (NCT02646748)
  • Boehringer Ingelheim: A Phase I Dose Escalation and CNS Pharmacokinetic Study of the ErbB Family Inhibitor Afatinib in Patients with Recurrent or Progressive Brain Cancer (NCT02423525)
  • Medicenna Therapeutics, Inc.: An Open-Label Non-Randomized, Multi-Center Phase-2 Study of Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma (NCT02858895)
  • Nativis: A Feasibility Study of the Nativis Voyager System in Patients With Recurrent Glioblastoma Multiforme (GBM)(NCT02296580)
  • NovoCure, Ltd.: A Single-Center, Open-Label, Randomized Phase II Study of NovoTTF-200A Alone and Combined With Temozolomide in Patients With Low-Grade Gliomas (NCT02507232)
  • Orbus Therapeutics: A Randomized Phase 3 Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine With Lomustine Compared to Lomustine Alone in Patients With Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy (NCT02796261)
  • Triphase MRZ-112: Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer (NCT02903069)

 

Brain Metastasis

  • Boehringer Ingelheim: A Phase I Dose Escalation and CNS Pharmacokinetic Study of the ErbB Family Inhibitor Afatinib in Patients with Recurrent or Progressive Brain Cancer (NCT02423525)
  • Eli Lilly and Company: A Phase 2 Study of Abemaciclib in Patients With Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer, Non-small Cell Lung Cancer, or Melanoma (NCT02308020)
  • Kadmon: Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases (NCT02616393)

 

Solid Tumors

  • Incyte Corporation: A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Pembrolizumab + INCB Combinations in Advanced Solid Tumors (NCT02646748)

 

Quality and Outcomes Research

  • CancerLife: Evaluation of a Mobile Digital Solution for Cancer Care and Research: A Feasibility Study (NCT03094741)
  • Family Caregivers: An Exploratory Study of Caregiver Burden Among Family Caregivers of Cancer Patients (NCT03069105)
FOR PROVIDERS: Clinical Trials Flyers

Details about each trial can be found in these downloadable information sheets.

AbbieVie

Boeringer Ingelheim

Boston BioMedical

CancerLife

Eli Lilly

Family Caregiver

Kadmon

Medicenna

Nativis

Novocure

Orbus

Triphase

For more information, contact the Neuro-oncology Clinical Trials Team at neuro.oncology@jwci.org or 310-829-8265.